论文部分内容阅读
目的:探讨阿托伐他汀在冠心病患者中疲乏发生率及对服药顺应性影响。方法:入选介入治疗的冠心病患者477例(A组)和药物治疗患者312例(B组)。观察两组疲乏发生率、疲乏程度、对服药顺应性影响等,检测服药后肌酸激酶(CK)、丙氨酸氨基转移酶(ALT)及低密度脂蛋白胆固醇(LDL-C)水平。结果:①两组患者的疲乏主要以轻度疲乏为主,A组的疲乏发生率明显高于B组,并且A组的疲乏发生率更多的发生在服药后0～3个月内;②调整阿托伐他汀类药物可以部分而不是全部缓解疲乏症状;③两组患者CK、ALT及LDL-C水平无明显差异,但重度疲乏患者CK浓度明显高于轻、中度疲乏患者。结论:阿托伐他汀钙片引起的疲乏以轻度疲乏为主,在接受介入治疗的患者中疲乏的发生率偏高。
Objective: To investigate the incidence of fatigue and its compliance with atorvastatin in patients with coronary heart disease. Methods: 477 patients with coronary heart disease (group A) and 312 patients with drug treatment (group B) were enrolled in this study. The incidences of fatigue, fatigue and compliance with medication were observed. The levels of creatine kinase (CK), alanine aminotransferase (ALT) and low density lipoprotein cholesterol (LDL-C) were measured after treatment. Results: (1) The fatigue of the two groups was mainly mild fatigue, the fatigue of group A was significantly higher than that of group B, and the incidence of fatigue in group A occurred more frequently within 0-3 months after taking medicine. Adjustment of atorvastatin can relieve fatigue partly, but not totally. ③ There was no significant difference in CK, ALT and LDL-C between the two groups, but the CK concentration in severe fatigue group was significantly higher than that in mild and moderate fatigue group. Conclusion: Atorvastatin calcium-based fatigue was mainly mild fatigue, and the incidence of fatigue was high in patients undergoing interventional therapy.